131 studies found for:    'Immunodeficiency NOT AIDS | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
Condition: Severe Immunodeficiency Diseases
Intervention: Drug: Fludarabine, Busulfan, and Anti-Thymocyte Globulin
2 Unknown  Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Conditions: Common Variable Immunodeficiency;   Granulomatous Disease;   Bronchiectasis;   Immunoglobulin Treatment
Intervention:
3 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
4 Recruiting Pharmacokinetics (PK) and Safety of Subgam®VF in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyperimmunoglobulin M Syndrome
Intervention: Biological: Subgam
5 Not yet recruiting Novel Testing Procedures
Condition: Immunodeficiencies
Intervention:
6 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
7 Not yet recruiting Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
Condition: Severe Combined Immunodeficiency
Intervention: Genetic: gene sequencing
8 Recruiting Generalized Neonatal Screening of Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency, Atypical
Intervention: Biological: SCID screening
9 Unknown  "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency
Condition: Common Variable Immunodeficiency
Interventions: Biological: PPS;   Biological: PnCJ PPS
10 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
11 Recruiting Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
Condition: Severe Combined Immunodeficiency Disease, X-linked
Interventions: Genetic: CL20-4i-EF/a-hyc-OPT;   Drug: Busulfan
12 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
13 Not yet recruiting A Two Cohort, Open-Label, Prospective, Multicenter Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous in Subjects With Primary Immunodeficiency Diseases
Condition: Primary Immunodeficiency
Intervention: Biological: Immune Globulin (Human) Intravenous
14 Recruiting Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Condition: Primary Immunodeficiency Disease (PIDD)
Intervention:
15 Unknown  Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
16 Recruiting Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-IgM Syndrome
Interventions: Biological: Gammaplex (5%);   Biological: Gammaplex 10
17 Recruiting Investigation of Immune Disorders and Deficiencies
Conditions: Primary Immune Deficiencies;   Autoimmune Diseases;   Inflammatory Diseases;   Common Variable Immune Deficiencies;   Hypogammaglobulinemia
Intervention:
18 Recruiting Diagnostic Immunization With Rabies Vaccine in Patients With PID
Condition: Primary Immunodeficiency
Intervention: Biological: Verorab® (PVRV; Purified Vero Cell Vaccine)
19 Recruiting Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes
Condition: CVID
Intervention:
20 Recruiting A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
Condition: Primary Immunodeficiency
Interventions: Device: Chrono Super PID then Generic Syringe-Gammanorm;   Device: Generic Syringe then Chrono Super PID-Gammanorm

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years